BioMed Valley Discoveries

BioMed Valley Discoveries is a clinical-stage biotechnology company founded in 2007 and based in Kansas City, Missouri. The company pursues a distinctive, patient-focused mission to develop groundbreaking medicines addressing unmet medical needs across multiple therapeutic areas including oncology, immunology, inflammation, infectious diseases, and rare diseases. Operating with a unique "de-risking" business model, BVD focuses on early-stage development through clinical proof-of-concept, targeting programs that may be considered too early, too risky, or too small for traditional biotech or pharmaceutical companies. BioMed Valley Discoveries is wholly owned by a supporting organization of the Stowers Institute for Medical Research and benefits from stable, long-term funding via the Stowers family's controlling interest in American Century Investments, freeing it from traditional venture capital pressures and short-term investor considerations. The company leverages hundreds of experts at leading academic and clinical institutions across its network of physician research collaborators and centers of excellence to advance therapeutic programs efficiently and cost-effectively. The company's current pipeline includes three clinical-stage programs: ulixertinib (BVD-523), a first-in-class ERK1/2 kinase inhibitor; Clostridium novyi-NT (CNV-NT/BVD-550), an oncolytic bacterial immunotherapy; and antibody-drug conjugate (ADC) programs targeting CD276 and TEM8. All programs focus on advancing cancer therapeutics through innovative mechanisms and rigorous clinical development.